Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel
antagonist of T prostanoid (TP) receptors, as a treatment for patients with
aspirin-exacerbated respiratory disease (AERD).